Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 833 of 6351
-
New hope for kidney cancer: triple therapy trial launches
Disease control Recruiting nowTo learn if giving 177Lu girentuximab in combination with cabozantinib plus nivolumab can help to control advanced clear cell renal cell carcinoma (ccRCC).
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
New cancer drug ART6043 enters human trials for advanced tumors
Disease control Recruiting nowThis interventional study will evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ART6043 as monotherapy or in combination with olaparib.
Phase 1/2 • Sponsor: Artios Pharma Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Breathing new hope: inhaled gene therapy trial for cystic fibrosis begins
Disease control Recruiting nowThis study will evaluate safety and tolerability of ascending doses of nebulized KB407 in adults with cystic fibrosis.
Phase 1 • Sponsor: Krystal Biotech, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Can a fertility drug boost miscarriage treatment success?
Disease control CompletedComparison of rate of complete abortion between Letrozole plus Misoprostol versus Misoprostol alone in first trimester pregnancy
Sponsor: Queen Savang Vadhana Memorial Hospital, Thailand • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Cold therapy may offer relief for Chemotherapy-Induced nerve pain in children
Symptom relief CompletedThis study examines the feasibility, acceptability, and efficacy of cold therapy on vincristine-induced peripheral neuropathy (VIPN) in pediatric patients with cancer. Vincristine (VCR) is one of the most used vinca alkaloid chemotherapy in pediatric oncology patients. It leads …
Sponsor: Koç University • Aim: Symptom relief
Last updated Sep 10, 2026 00:00 UTC
-
Surgical flap may open door to better brain tumor treatment
Disease control Recruiting nowThis single center, single arm, open-label, phase 2 study will assess the safety and efficacy of a pedicled temporoparietal fascial (TPF) or pericranial flap into the resection cavity of newly diagnosed glioblastoma multifome (GBM) patients. The objective of the Phase 2 study is…
Sponsor: Northwell Health • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Blood test could end guesswork in rheumatoid arthritis treatment
Knowledge-focused OngoingThe primary goal of this study is to assess a cfDNA-based blood test using genetic, transcriptomic and/or epigenetic information to help doctors predict the best treatment options for rheumatoid arthritis (RA) patients with inadequate response or intolerance to previous therapies…
Sponsor: Aqtual, Inc. • Aim: Knowledge-focused
Last updated Jul 23, 2026 00:00 UTC
-
New drug shows promise for slowing kidney disease in IgA nephropathy
Disease control OngoingA Phase 3 Study with Atacicept in Subjects With IgA Nephropathy (ORIGIN 3)
Phase 3 • Sponsor: Vera Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Hope for teens with down syndrome regression disorder: old drugs, new purpose
Disease control CompletedIndividuals with Down syndrome (DS) have an increased risk of numerous co-occurring conditions, including the neuropsychiatric condition known as Down Syndrome Regression Disorder (DSRD). A DSRD diagnosis often includes a sub-acute onset of catatonia, mutism, depersonalization, l…
Phase 2 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New drug cocktail aims to rescue patients from Hard-to-Treat lymphoma
Disease control OngoingThis phase II clinical trial evaluates tafasitamab and lenalidomide followed by tafasitamab and the carboplatin, etoposide and ifosfamide (ICE) regimen as salvage therapy for transplant eligible patients with large B-cell lymphoma that has come back (relapsed) or has not responde…
Phase 2 • Sponsor: David Bond, MD • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Can a virtual snub reveal how racism harms teen health?
Knowledge-focused CompletedThe goal of this study is to learn about whether ethnic minority adolescents' racial discrimination experience is related to dysregulated biological responses to subtle racism, and how the relationship may be attenuated or exacerbated by a set of social and cognitive factors. The…
Sponsor: Western Kentucky University • Aim: Knowledge-focused
Last updated Aug 19, 2026 00:00 UTC
-
New hope for rare nerve disease: rituximab trial targets good responders
Disease control Recruiting nowAnti-MAG neuropathy is a progressively disabling orphan rare disorder due to a monoclonal immunoglobulin M(IgM) gammopathy displaying reactivity toward MAG, a glycoprotein of the peripheral nervous system. Its prevalence is around 1/100000 and to date, no treatment has proven eff…
Phase 3 • Sponsor: Centre Hospitalier Universitaire de Saint Etienne • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Could a Synapse-Targeting drug slow Alzheimer's?
Disease control OngoingThis is a multicenter randomized, double-blind, placebo-controlled Phase 2 study designed to evaluate the efficacy, safety, and tolerability of two doses of CT1812 compared to placebo in participants diagnosed with early Alzheimer's disease.
Phase 2 • Sponsor: Cognition Therapeutics • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New hope for hard-to-treat myeloma: drug duo targets genetic weak spot
Disease control Recruiting nowThe goal of this clinical trial is to learn about the safety and efficacy of the drug combination belantamab mafodotin and venetoclax, with or without the addition of dexamethasone, in patients with relapsed/refractory multiple myeloma bearing the translocation t(11;14)
Phase 1/2 • Sponsor: Universitätsklinikum Hamburg-Eppendorf • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New combo pill aims to tame stubborn high blood pressure
Disease control CompletedThe main objective of the study will be to assess the efficacy and safety of Sacubitril/Allisartan (240mg) and Amlodipine (5mg) in patients with essential hypertension uncontrolled after 4-week treatment with Amlodipine (5mg).
Phase 3 • Sponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
One-Week radiation blasts recurrent breast cancer, spares healthy tissue
Disease control Recruiting nowBreast-conserving surgery followed by re-irradiation with partial breast irradiation (rPBI) has recently been found to be a safe alternative to mastectomy for women who have undergone prior whole breast radiation. By reducing the volume of tissue receiving radiation, rPBI has bee…
Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Two-Drug cocktail aims to beat back rare bone marrow cancers
Disease control OngoingThis phase II trial tests whether decitabine and cedazuridine (ASTX727) in combination with venetoclax work better than ASTX727 alone at decreasing symptoms of bone marrow cancer in patients with chronic myelomonocytic leukemia (CMML), myelodysplastic syndrome/myeloproliferative …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
New combo therapy aims to stall prostate cancer spread
Disease control Recruiting nowMulticenter, open-label, parallel-group, phase II randomized study in patients with oligometastatic prostate cancer with 1-3 asymptomatic metastases of the soft tissue or bone. Eligible patients will be randomized at 1:1 ratio to Stereotactic Radiotherapy followed by Lu-PSMA (arm…
Phase 2 • Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New drug cocktail shows promise for tough lung cancer mutation
Disease control OngoingThis study is designed to evaluate the efficacy and safety of Pembrolizumab in combination with Bevacizumab and chemotherapy in advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutation.
Phase 2 • Sponsor: Shanghai Chest Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Magic mushroom compound tested to calm cancer anxiety
Symptom relief CompletedThis phase I/II trial tests the safety and side effects of psilocybin in combination with therapy for the treatment of patients with metastatic cancer and symptoms of anxiety and/or depression. Psilocybin is a substance being studied in conjunction with therapy for the treatment …
Phase 1/2 • Sponsor: University of Washington • Aim: Symptom relief
Last updated Jun 27, 2026 07:56 UTC